OBIO News - Candlesense

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

NEW HOPE, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact tech...

What reimbursement pathways are anticipated for AVIM therapy, and what timeline is expected for coverage decisions? How might the data influence the company's earnings guidance or revenue forecasts for the next fiscal year? Is there potential for strategic partnerships, licensing deals, or acquisition interest following the publication in JACC: Advances?

Clinical trials

10 days ago

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

NEW HOPE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...

Are there any changes in the senior management or board that could affect strategic direction? What is the market’s reaction to this release (e.g., price movement, volume) and how does it compare to analyst expectations? Did the company provide any updates on the status of its key clinical programs and their timelines?

Earnings

12 days ago

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

NEW HOPE, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...

What are the potential implications for the valuation of OBIO's pipeline if the BACKBEAT study demonstrates positive outcomes with the larger patient pool? Are there any anticipated changes in operating expenses or capital requirements associated with the expanded trial that could affect profitability margins? How might the market react to the news sentiment score of 70 and the potential for higher trial enrollment numbers?

Clinical trials

16 days ago